Literature DB >> 23359867

SUMO modification of menin.

Zi-Jie Feng1, Buddha Gurung, Guang-Hui Jin, Xiao-Lu Yang, Xian-Xin Hua.   

Abstract

Menin acts as contextual a tumor suppressor and a tumor promoter, partly via epigenetic regulation of gene transcription. While menin is phosphorylated, it remains unclear whether wild type menin has other post-translational modifications. Here, we report that menin is SUMOylated by SUMO1 in vivo and in vitro, and the SUMOylation is reduced by a SUMO protease. Lysine 591 of menin was covalently modified by SUMO1 and K591R mutation in menin blocked SUMOylation of the C-terminal part of menin in transfected cells. Full-length menin with K591 mutation was still SUMOylated in vivo, suggesting the existence of multiple SUMOylation sites. Menin K591R mutant or menin-SUMO fusion protein still retains the ability to regulate cell proliferation and the expression of the examined menin target genes.

Entities:  

Keywords:  K591R; Menin; SUMO1; SUMOylation

Year:  2013        PMID: 23359867      PMCID: PMC3555195     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  35 in total

1.  SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting.

Authors:  M S Rodriguez; C Dargemont; R T Hay
Journal:  J Biol Chem       Date:  2000-12-21       Impact factor: 5.157

2.  Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity.

Authors:  Darja Schmidt; Stefan Müller
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

Review 3.  SUMO: ligases, isopeptidases and nuclear pores.

Authors:  Frauke Melchior; Marion Schergaut; Andrea Pichler
Journal:  Trends Biochem Sci       Date:  2003-11       Impact factor: 13.807

Review 4.  Protein modification by SUMO.

Authors:  Erica S Johnson
Journal:  Annu Rev Biochem       Date:  2004       Impact factor: 23.643

5.  Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin.

Authors:  K Orford; C Crockett; J P Jensen; A M Weissman; S W Byers
Journal:  J Biol Chem       Date:  1997-10-03       Impact factor: 5.157

6.  Positional cloning of the gene for multiple endocrine neoplasia-type 1.

Authors:  S C Chandrasekharappa; S C Guru; P Manickam; S E Olufemi; F S Collins; M R Emmert-Buck; L V Debelenko; Z Zhuang; I A Lubensky; L A Liotta; J S Crabtree; Y Wang; B A Roe; J Weisemann; M S Boguski; S K Agarwal; M B Kester; Y S Kim; C Heppner; Q Dong; A M Spiegel; A L Burns; S J Marx
Journal:  Science       Date:  1997-04-18       Impact factor: 47.728

7.  Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1.

Authors:  I Lemmens; W J Van de Ven; K Kas; C X Zhang; S Giraud; V Wautot; N Buisson; K De Witte; J Salandre; G Lenoir; M Pugeat; A Calender; F Parente; D Quincey; P Gaudray; M J De Wit; C J Lips; J W Höppener; S Khodaei; A L Grant; G Weber; S Kytölä; B T Teh; F Farnebo; R V Thakker
Journal:  Hum Mol Genet       Date:  1997-07       Impact factor: 6.150

8.  Menin missense mutants associated with multiple endocrine neoplasia type 1 are rapidly degraded via the ubiquitin-proteasome pathway.

Authors:  Hiroko Yaguchi; Naganari Ohkura; Maho Takahashi; Yuko Nagamura; Issay Kitabayashi; Toshihiko Tsukada
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

9.  Structure determination of the small ubiquitin-related modifier SUMO-1.

Authors:  P Bayer; A Arndt; S Metzger; R Mahajan; F Melchior; R Jaenicke; J Becker
Journal:  J Mol Biol       Date:  1998-07-10       Impact factor: 5.469

10.  Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1.

Authors:  Philippe Bertolino; Wei-Min Tong; Dominique Galendo; Zhao-Qi Wang; Chang-Xian Zhang
Journal:  Mol Endocrinol       Date:  2003-06-20
View more
  9 in total

Review 1.  Challenges and opportunities in targeting the menin-MLL interaction.

Authors:  Tomasz Cierpicki; Jolanta Grembecka
Journal:  Future Med Chem       Date:  2014-03       Impact factor: 3.808

2.  Menin and Daxx Interact to Suppress Neuroendocrine Tumors through Epigenetic Control of the Membrane Metallo-Endopeptidase.

Authors:  Zijie Feng; Lei Wang; Yanmei Sun; Zongzhe Jiang; John Domsic; Chiying An; Bowen Xing; Jingjing Tian; Xiuheng Liu; David C Metz; Xiaolu Yang; Ronen Marmorstein; Xiaosong Ma; Xianxin Hua
Journal:  Cancer Res       Date:  2016-11-21       Impact factor: 12.701

3.  An improved method for identifying SUMOylation sites of viral proteins.

Authors:  Yan Liu; Zhongyuan Tan; Bo Shu; Yuan Zhang; Caishang Zheng; Xianliang Ke; Xi Chen; Hanzhong Wang; Zhenhua Zheng
Journal:  Virol Sin       Date:  2017-12       Impact factor: 4.327

Review 4.  Epigenetic regulation by the menin pathway.

Authors:  Zijie Feng; Jian Ma; Xianxin Hua
Journal:  Endocr Relat Cancer       Date:  2017-08-15       Impact factor: 5.678

Review 5.  Menin: a scaffold protein that controls gene expression and cell signaling.

Authors:  Smita Matkar; Austin Thiel; Xianxin Hua
Journal:  Trends Biochem Sci       Date:  2013-07-10       Impact factor: 13.807

6.  Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues.

Authors:  Zijie Feng; Xin He; Xuyao Zhang; Yuan Wu; Bowen Xing; Alison Knowles; Qiaonan Shan; Samuel Miller; Taylor Hojnacki; Jian Ma; Bryson W Katona; Terence P F Gade; Jörg Schrader; David C Metz; Carl H June; Xianxin Hua
Journal:  Nat Cancer       Date:  2022-03-21

Review 7.  The future: genetics advances in MEN1 therapeutic approaches and management strategies.

Authors:  Sunita K Agarwal
Journal:  Endocr Relat Cancer       Date:  2017-10       Impact factor: 5.678

8.  Sumoylation pathway is required to maintain the basal breast cancer subtype.

Authors:  Maria V Bogachek; Yizhen Chen; Mikhail V Kulak; George W Woodfield; Anthony R Cyr; Jung M Park; Philip M Spanheimer; Yingyue Li; Tiandao Li; Ronald J Weigel
Journal:  Cancer Cell       Date:  2014-05-15       Impact factor: 31.743

Review 9.  Multiple Endocrine Neoplasia Type 1: Latest Insights.

Authors:  Maria Luisa Brandi; Sunita K Agarwal; Nancy D Perrier; Kate E Lines; Gerlof D Valk; Rajesh V Thakker
Journal:  Endocr Rev       Date:  2021-03-15       Impact factor: 19.871

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.